Pharma BD Deal Intelligence
A PE take-private that worked exactly as designed: Pamplona Capital bought PAREXEL for approximately $5.0B in cash in 2017, then sold the clinical research outsourcing platform for $8.5 billion in 2021—a roughly 70% value gain achieved through a new CEO and bolt-on technology acquisitions.
A PE take-private that worked exactly as designed: bought for ~$5.0B in 2017, sold for $8.5B in 2021 — a ~70% value gain in four years plus successful bolt-on M&A along the way.
Full analysis, sources & comparables →BioPharma Dive framed the take-private as the latest in a wave of CRO consolidation, contextualizing it alongside the QuintilesIMS and INC/inVentiv mergers and…
FierceBiotech highlighted the activist-led process that culminated in the Pamplona deal, noting Starboard, Jana and Corvex pressure pushed PAREXEL to explore a…
Pamplona's 2021 exit at $8.5B to EQT and Goldman Sachs Asset Management vindicated the original take-private thesis, with FierceBiotech noting the 70% gain on…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
PAREXEL agreed to be taken private by Pamplona Capital for $88.10/share in cash, transaction valued at approximately $5B and representing a 27.9% premium over the May 5, 2017 unaffected closing price. PAREXEL provides full-service drug development outsourcing including clinical trials, regulatory consulting and reimbursement strategy. Transaction closed September 2017.
A PE take-private that worked exactly as designed: bought for ~$5.0B in 2017, sold for $8.5B in 2021 — a ~70% value gain in four years plus successful bolt-on M&A along the way.
Assessment window: 5yr post-close.
$45.5B Global CRO market 2017
Contract research organizations (CROs) provide outsourced drug development services across clinical trial design and execution, regulatory affairs, pharmacovigilance, market access and commercialization consulting. CROs have grown structurally as biopharma sponsors variabilize R&D cost, with rising complexity in oncology, rare disease and biologics fueling demand for specialized capabilities.
At deal time (June 2017) the CRO market was in active consolidation. Quintiles and IMS Health had merged in 2016 to create QuintilesIMS (later IQVIA), the new market leader. INC Research and inVentiv Health announced their merger in May 2017 to form Syneos Health. Other top-five players included Covance (LabCorp), PRA Health Sciences, ICON plc, and Charles River Laboratories. PAREXEL's go-private with Pamplona Capital at $88.10/share — a 27.9% premium to the unaffected price — was driven by activist pressure: Starboard Value disclosed a 5.7% stake in May 2017 calling shares 'substantially undervalued,' and Jana Partners and Corvex also accumulated positions. PAREXEL's profit margins lagged peers, and Pamplona's thesis centered on operational restructuring outside public-market scrutiny — PAREXEL announced 1,200 job cuts and offshoring shortly after closing. Pamplona ultimately exited in 2021 by selling PAREXEL to EQT and Goldman Sachs at $8.5B — a 70% gain on the original $5B take-private.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pamplona Capital Management, LLP / PAREXEL International Corporation (this deal) | 2017 | $5.0B | 90 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
← Browse all deals · How we score deals
More: 2017 deals · Other deals